MedTrace Logo

Mexidol® Efficacy and Safety in Treatment of VCIND in Older Adults

NCT07700615 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2026-07-14

No results posted yet for this study

Summary

The primary objective of this study is to evaluate the efficacy of Mexidol® sequential parenteral and oral administration as part of comprehensive therapy in older adults with chronic brain ischemia and vascular cognitive impairment, no dementia (VCIND).

Conditions

  • Vascular Cognitive Impairment no Dementia

Interventions

DRUG

Mexidol

In addition to standard therapy, Mexidol sequential therapy was administered in two phases: * Days 1 to 5: Intravenous (IV) infusion of 10 mL (500 mg) once daily, diluted in 100-150 mL of 0.9% sodium chloride solution. Infusion rate: 40-60 drops per minute. * Days 6 to 65: Oral administration of Mexidol® FORTE 250 mg tablets, 1 tablet 3 times daily (750 mg total daily dose) for 60 consecutive days.

OTHER

Standard Therapy

Standard background therapy administered in accordance with institutional protocols and applicable clinical guidelines, including cognitive training.

Sponsors & Collaborators

  • Pharmasoft

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-14
Primary Completion
2025-11-05
Completion
2025-11-05

Countries

  • Russia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07700615 on ClinicalTrials.gov